Combined Treatment with an LHRH Agonist and the Antiandrogen Flutamide in Prostate Cancer

  • F. Labrie
  • A. Dupont
  • A. Belanger
  • R. St. Arnaud
  • M. Giguere
  • Y. Lacourciere
  • J. Emond
  • G. Monfette
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

The original observation that treatment of adult male rats with LHRH agonists causes a marked inhibition of testosterone secretion accompanied by a loss in secondary sex organ weight (Labrie et ai, 1978, 1980) opened a new era in the treatment of androgen-dependent diseases. When administered to adult men in appropriate doses by the subcutaneous route, these peptides decrease serum testosterone and dihydrotestosterone to castrated levels (Labrie et al., 1980; Faure et ai, 1982; Jacobi and Wenderoth, 1982). Since LHRH agonists have no adverse side effects other than those related to low circulating levels of androgens, they offer an advantageous alternative to orchiectomy and treatment with estrogens in advanced carcinoma of the prostate.

Keywords

Estrogen Cortisol Testosterone Androgen Androstenedione 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armitage, T., 1971, Statistical Methods in Medical Research, Blackwell Scientific, Oxford.Google Scholar
  2. Bartsch, W., Knabbe, B., and Voigt, K. D., 1983, Regulation and compartmentalization of androgens in rat prostate and muscle, J. Steroid Biochem. 19:929–937.PubMedCrossRefGoogle Scholar
  3. Faure, N., Labrie, F., Lemay, A., Bélanger, A., Gourdeau, Y., Laroche, B., and Robert, G., 1982, Inhibition of serum androgen levels by chronic intranasal administration of a potent LHRH agonist in adult men, Fertil. Steril. 37:416–424.PubMedGoogle Scholar
  4. Geller, J., Albert, J. D., Nachtsheim, D. A., and Loza, D. C., 1984, Comparison of prostatic cancer tissue dehydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy, J. Urol. 132:693–696.PubMedGoogle Scholar
  5. Goldman, A. J., and Elwood, J. M., 1979, Examining survival data, CMA J. 121:1065–1071.Google Scholar
  6. Harper, M. E., Pike, A., Peeling, W. B., and Griffiths, K., 1974, Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro, J. Endocrinol. 60:117–125.PubMedCrossRefGoogle Scholar
  7. Huggins, C., and Scott, W. W., 1945, Bilateral adrenalectomy in prostatic cancer, Ann. Surg. 122:1031–1041.CrossRefGoogle Scholar
  8. Jacobi, G. H., and Wenderoth, U. K., 1982, Gonadotropin-releasing hormone analogs for prostatic cancer: Untoward side-effects of high dose regimens acquire a therapeutical dimension, Eur. Urol. 8:129–134.PubMedGoogle Scholar
  9. Jordan, W. P., Jr., Blackard, C. E., and Byar, D. P., 1977, Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma, South. Med. J. 70:1411–1413.PubMedGoogle Scholar
  10. Kahan, A., Delrieu, F., Amor, B., Chiche, R., and Steg, A., 1984, Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer, Lancet 1:971–972.PubMedCrossRefGoogle Scholar
  11. Kaplan, E. L., and Meier, P., 1958, Nonparametric estimation from incomplete observations, Am. Statist. Assoc. J. 53:457–481.Google Scholar
  12. King, R. J. B., Cambray, G. J., Jagus-Smith, R., Robinson, J. H., and Smith, J. A., 1977, Steroid hormone and the control of tumor growth: Studies on androgen-responsive tumor cells in culture, in: Receptors and Mechanism of Action of Steroid Hormones (J. R. Pasqualini, ed.), Marcel Dekker, New York, pp. 215–227.Google Scholar
  13. Labrie, F., Auclair, C., Cusan, L., Kelly, P. A., Pelletier, G., and Ferland, L., 1978, Inhibitory effects of LHRH and its agonists on testicular gonadotrophin receptors and spermatogenesis in the rat, Int. J. Androl. [Suppl.]2:303–318.CrossRefGoogle Scholar
  14. Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P. A., Lefebvre, F. A., Lemay, A., and Raynaud, J. P., 1980, Antifertility effects of LHRH agonists in the male, J. Androl. 1:209–228.Google Scholar
  15. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacoursière, Y., Monfette, G., Laberge, J. G., Emond, J. P., Fazekas, A. T. A., Raynaud, J. P., and Husson, J. M., 1982, New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen, Clin. Invest. Med. 5:267–275.PubMedGoogle Scholar
  16. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Raynaud, J. P., Husson, J M., Gareau, J., Fazekas, A. T. A., Sandow, J., Monfette, G., Girard, J. G., Emond, J. P., and Houle, J. G., 1983a, New approach in the treatment of prostate cancer: Complete instead of only partial withdrawal of androgens, Prostate 4:579–594.PubMedCrossRefGoogle Scholar
  17. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F. A., Cusan, L., Monfette, G., Laberge, J. G., Emond, J P., Raynaud, J. P., Husson, J. M., and Fazekas, A. T. A., 1983b, New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antian-drogen, J. Steroid Biochem. 19:999–1008.PubMedCrossRefGoogle Scholar
  18. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., and Monfette, G., 1984, Combined treatment with an LHRH agonist and a pure antiandrogen in advanced carcinoma of the prostate, Lancet 1:1090.CrossRefGoogle Scholar
  19. Labrie, F., Dupont, A., and Bélanger, A., 1985, Complete androgen blockade for the treatment of prostate cancer, in: Important Advances in Oncology (V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg, eds.), J. B. Lippincott, Philadelphia, pp. 193–217.Google Scholar
  20. Leuprolide Study Group, 1984, Leuprolide versus diethylstilbestrol for metastatic prostate cancer, N. Engl. J. Med. 311:1281–1286.CrossRefGoogle Scholar
  21. Luthy, I., and Veilleux, R., 1985, The antiandrogen Flutamide® prevents the loss of androgen responsiveness in SC-115 mouse mammary carcinoma cells, in: Proceedings 67th Annual Meeting Endocrine Society, p. 193.Google Scholar
  22. Mettlin, C., Natarajan, N., and Murphy, G. P., 1982, Recent patterns of care of prostatic cancer patients in the United States: Results from the surveys of the American College of Surgeons Commission on Cancer, Int. Adv. Surg. Oncol. 5:277–321.PubMedGoogle Scholar
  23. Murphy, G. P., Beckley, S., Brady, M. F., Chu, M., DeKernion, J. B., Dhabuwala, C., Gaeta, J. F., Gibbons, R. P., Loening, S., McKiel, C. F., McLeod, D. G., Pontes, J. E., Prout, G. R., Scardino, P. T., Schlegel, J. U., Schmidt, J. D., Scott, W. W., Slack, N. H., and Soloway, M., 1983, Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone, Cancer 51:1264–1272.PubMedCrossRefGoogle Scholar
  24. Nesbit, R. M., and Baum, W. C., 1950, Endocrine control of prostatic carcinoma: Clinical and statistical survey of 1818 cases, J.A.M.A. 143:1317–1320.CrossRefGoogle Scholar
  25. Robinson, M. R. G., Shearer, R. J., and Fergusson, J. D., 1974, Adrenal suppression in the treatment of carcinoma of the prostate, Br. J. Urol. 46:555–559.PubMedCrossRefGoogle Scholar
  26. Simard, J., and Labrie, F., 1984, Unoccupied androgen receptors are biologically active in rat pituitary gonadotrophs. Excerpta Medica Congr. Ser. 652:9Google Scholar
  27. Slack, N. H., Murphy, G. D., and NPCP participants, 1984, Criteria for evaluating patient responses to treatment modalities for prostatic cancer, Urol Clin. North Am. 11:337–342.PubMedGoogle Scholar
  28. Sogani, P. C., Ray, B., and Whitmore, W. F. Jr., 1975, Advanced prostatic carcinoma: Flutamide® therapy after conventional endocrine treatment, Urology 6:164–166.PubMedCrossRefGoogle Scholar
  29. St.-Arnaud, R., Lachance, R., Kelly, S. J., Bélanger, A., Dupont, A., and Labrie, F., 1986, Loss of luteinizing hormone (LH) bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen, Clin. Endocrinol. 24:21–30.CrossRefGoogle Scholar
  30. Stoliar, B., and Albert, D. J., 1974, SCH 13521 in the treatment of advanced carcinoma of the prostate, J. Urol. 111:803–807.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • F. Labrie
    • 1
  • A. Dupont
    • 1
  • A. Belanger
    • 1
  • R. St. Arnaud
    • 1
  • M. Giguere
    • 1
  • Y. Lacourciere
    • 1
  • J. Emond
    • 2
  • G. Monfette
    • 2
  1. 1.Departments of Medicine, Molecular Endocrinology and UrologyLaval University Medical CenterCanada
  2. 2.Hôtel-Dieu HospitalCanada

Personalised recommendations